Integra LifeSciences (NASDAQ:IART - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.400-0.450 for the period, compared to the consensus EPS estimate of 0.577. The company issued revenue guidance of $410.0 million-$420.0 million, compared to the consensus revenue estimate of $418.8 million. Integra LifeSciences also updated its FY 2025 guidance to 2.190-2.290 EPS.
Analyst Ratings Changes
Several analysts have weighed in on the company. Truist Financial dropped their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. JMP Securities dropped their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Wells Fargo & Company lowered their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of "Hold" and an average price target of $18.63.
Check Out Our Latest Stock Analysis on IART
Integra LifeSciences Price Performance
Shares of Integra LifeSciences stock traded down $0.83 during mid-day trading on Friday, reaching $12.31. 2,230,460 shares of the stock traded hands, compared to its average volume of 1,037,569. The stock has a market capitalization of $956.61 million, a PE ratio of -1.89, a PEG ratio of 0.69 and a beta of 1.16. Integra LifeSciences has a fifty-two week low of $11.06 and a fifty-two week high of $27.13. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average of $12.60 and a 200 day moving average of $17.63.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 11.18% and a negative net margin of 30.87%. The business had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. During the same period last year, the business posted $0.63 earnings per share. The company's quarterly revenue was down .6% on a year-over-year basis. On average, analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in Integra LifeSciences in the first quarter valued at $277,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock valued at $889,000 after buying an additional 1,975 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock valued at $5,373,000 after buying an additional 45,693 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock valued at $36,515,000 after buying an additional 35,790 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
